Illumina forms 15-year cancer sequencing deal with Roche

Although it faced a setback earlier this month when regulators put the kibosh on its deal to acquire a rival company, genetic sequencing equipment maker Illumina will leave the J.P. Morgan Healthcare Conference with two new partnering deals under its belt. The San Diego-based company and Swiss drug and diagnostics maker Roche said Monday that they had formed a partnership to increase availability of genomic testing to patients with cancers. The 15-year, non-exclusive partnership is meant to broaden adoption of distributable next-generation sequencing-based testing in oncology. Financial terms between Illumina and Roche were not disclosed.